Top Electroceuticals Bioelectric Medicine Companies

Due to the sheer number of manufacturers, the market is very fragmented. Major producers offer a wide selection of cutting-edge electroceuticals through their effective global distribution networks. It has sparked fierce competition between manufacturers and put great pressure on vendors' pricing tactics, both of which are projected to have an impact on the profit margin. The leading companies in this industry are also well-known, established, and have a lot of brand loyalty. Newcomers must therefore compete with established competitors and differentiate themselves by creating novel product offerings. For instance, the Platform with Differential Target Multiplexed (DTM) programming from Medtronic plc (IrelandIntellis) was approved by the US FDA in March 2021 to treat chronic, unrelieved back and leg pain.

Top Players in Electroceuticals Bioelectric Medicine Market

• Medtronic (Ireland) 
• Abbott (US) 
• Boston Scientific Corporation (US) 
• Cochlear Ltd. (Australia) 
• LivaNova PLC (UK) 
• Biotronik SE & Co. KG (Germany) 
• electroCore, Inc. (US) 
• Sonova (Switzerland) 
• Nevro Corp. (US) 
• Stimwave LLC (US) 
• SetPoint Medical (US) 
• Sky Medical Technology (UK) 
• Cala Health (US) 
• NeuroPace, Inc. (US) 
• Koninklijke Philips N.V. (Netherlands) 
• WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany) 
• Sonova Holding AG (Switzerland) 
• Oticon Medical AB (Denmark) 
• BioElectronics Corporation (US) 
• MicroTransponder Inc. (US)

Electroceuticals Bioelectric Medicine Market Recent Development

• In January 2022, the first Bioelectronic Medicine Day, which included a health awareness campaign, was introduced by the Alliance for Advancing Bioelectronic Medicine. The campaign backed initiatives and developments in the area of bioelectronic medicine.
• In July 2021, Graphene-based bioelectronic vagus nerve therapies for severe chronic disorders are being developed by Innervia Bioelectronics in collaboration with Merck KGaA, Darmstadt, Germany (Merck). The collaboration will use the knowledge of both businesses to develop treatments for illnesses with unmet medical needs that fall under Merck's purview of therapeutic spheres.
• In February 2021, the first clinic patients have been treated with the CellFX System, according to Pulse Biosciences, Inc., a cutting-edge bioelectric medicine business advancing Nano-Pulse Stimulation (NPS) technology. The CellFX System's initial commercial application heralds the start of the company's controlled launch campaign with product shipments to esteemed dermatology authorities in the US and Europe.